It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the ...

French researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and ...

Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster ...

to examine potential applications of glucagon-like peptide-1 receptor (GLP-1R) agonists in central nervous system disorders, such as dementia, Parkinson’s disease, substance and alcohol use disorders, ...

As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists ...

GLP-1RA vs insulin use was associated with improved cardiovascular and kidney outcomes among patients with type 2 diabetes on dialysis.

French researchers have developed a new drug delivery system that could cut the dosing schedule for type 2 diabetes and ...

Pricey glucagon-like peptide 1 drugs, or GLP-1s, for weight loss are also projected to increase spending. Most non-elderly Americans receive health insurance coverage through their employers ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...